Diaceutics (DXRX.L) Osake Kurssi
Diaceutics Kurssi
Viimeisten 8 vuoden aikana Diaceuticsn liikevaihto kasvoi 27,6 % vuodessa ja ylsi 32,16 M GBP:een. Osakekohtainen tulos on laskenut 4,0 % vuodessa viimeisten 6 vuoden aikana. Diaceuticsn nettomarginaali −5,3 % on laskenut verrattuna 2,1 %:iin muutama vuosi sitten. Diaceuticsn 12 kuukauden konsensustavoitehinta on 229,50 GBP, noin yli kurssia 11 520,3 %. 9 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
Diaceutics osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Diaceutics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Diaceutics -osakkeesta
The business model of Diaceutics PLC focuses on providing personalized diagnostics solutions and services to the pharmaceutical industry. Diaceutics helps pharmaceutical companies and laboratories optimize their diagnostic testing processes, ensuring patients receive accurate and timely test results. By harnessing real-world data and leveraging their expertise in diagnostic commercialization, the company enables precision medicine and improves patient outcomes. With a comprehensive approach that includes strategic consulting, data analytics, and software solutions, Diaceutics aims to bridge the gap between diagnostic testing and the delivery of targeted therapies.
Diaceutics PLC is primarily active in the healthcare and pharmaceutical industries. As a leading diagnostic commercialization company, Diaceutics specializes in helping pharmaceutical companies and laboratories improve patient outcomes through the delivery of precision medicine. With their extensive expertise in data analytics and laboratory network management, Diaceutics empowers healthcare providers to effectively integrate diagnostic testing into patient treatment pathways, thereby enhancing personalized medicine.
The main competitors of Diaceutics PLC in the market include companies such as LabCorp, QIAGEN, Foundation Medicine, and Genomic Health.
Diaceutics PLC is a leading data analytics and implementation services provider in the personalized medicine industry. Founded in 2005, the company has grown steadily and garnered a strong reputation for its expertise in diagnostic testing. It enables pharmaceutical companies, laboratories, and healthcare providers to optimize the use of targeted therapies for patients by leveraging advanced data analytics. Diaceutics PLC's robust platform helps bridge the gap between diagnostic testing and personalized medicine, significantly improving patient outcomes. With its deep industry knowledge and proprietary data-driven solutions, the company has become a trusted partner for life science companies globally, unlocking the potential of precision medicine.
Diaceutics PLC, a leading diagnostic data analytics and implementation services provider, has achieved several significant milestones. Firstly, the company successfully listed on the AIM market of the London Stock Exchange in March 2019, marking a major achievement in terms of financial market recognition. Additionally, Diaceutics has experienced substantial growth, expanding its global reach and establishing strategic partnerships with renowned pharmaceutical companies. Moreover, the company has received multiple awards and recognition for its innovative and impactful contributions to precision medicine. Diaceutics PLC's remarkable achievements are a testament to its commitment to revolutionizing the way healthcare providers utilize diagnostic testing, ultimately improving patient outcomes.
Diaceutics PLC is primarily present in multiple countries and regions worldwide. The company operates globally, with a strong presence in the United States, Europe, and key Asian markets. This includes countries such as the United Kingdom, Germany, France, Spain, Italy, China, Japan, and Australia, among others. With its expansive reach, Diaceutics PLC caters to healthcare providers, pharmaceutical companies, and diagnostic laboratories in various regions, enabling better personalized medicine and improving patient outcomes.
Diaceutics PLC represents a strong commitment to revolutionizing patient testing in the global diagnostic industry. The company's corporate philosophy is rooted in driving better patient outcomes by improving diagnostic testing for precision medicine. With a focus on leveraging data analytics and deep industry knowledge, Diaceutics PLC aims to bridge the gap between diagnostic testing and targeted therapies. By partnering with pharmaceutical companies, laboratories, and healthcare providers, Diaceutics PLC strives to enable faster and more accurate testing to ensure patients receive the right treatment at the right time. Through innovation, collaboration, and patient-centricity, Diaceutics PLC is dedicated to empowering precision medicine and transforming healthcare.
Analyytikot asettavat tällä hetkellä Diaceutics-osakkeelle keskimääräisen tavoitehinnan 223,89 GBP (mediaani: 229,50 GBP), mikä merkitsee +13,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 9 analyytikkoarvioon.
9 analyytikkoa arvioi tällä hetkellä Diaceutics-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Diaceutics-yhtiöltä 46,72 M GBP liikevaihtoa ja 0,01 GBP osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Diaceutics-osake noteerataan hintaan 2,37 EUR (1,98 GBP).
Diaceutics-osake (DXRX.L) on listattuna 4 pörssissä, muun muassa: London (DXRX.L), Frankfurt (7DC.F).
Diaceutics PLC is an international company specializing in improving the diagnostics and care of cancer patients. The company's business model is based on the use of data analysis to understand the connections between diagnostics, therapy, and patient outcomes in order to optimize cancer treatment.
odotettu liikevaihto Diaceutics on 46,72 M GBP. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Diaceutics on 1,04 M GBP. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Diaceutics:n hinta-voitto-suhde (P/E) on tällä hetkellä 160,89. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Diaceutics-osakkeen arvostusta.
Diaceutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,57. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Diaceutics-osakkeen arvostuskennuslukuna.
Diaceutics:n Eulpool-laatuscore on 3/10.
Diaceutics:n ISIN on GB00BJQTGV64. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Diaceutics:n WKN on A2PF80. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Diaceutics:n ticker on DXRX.L. Tämä pörssinoteeraus käytetään Diaceutics-osakkeiden kauppaan pörssissä.
Diaceutics osake
Diaceutics vertaisryhmä
Diaceutics Ticker
Diaceutics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Diaceutics:sta
Meidän osakeanalyysimme Diaceutics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Diaceutics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: